According to the statistics of dolphin stock data, as of the closing, the stock price of North China Pharmaceutical was 7.58 yuan, with a rise and fall of -2.19%, a turnover rate of 1.78%, and a transaction of 220 million yuan throughout the day.
01. Funding Interpretation
Today, the stock's main funds inflowed 61.63 million yuan, outflowed 97 million yuan, and net outflowed 35.37 million yuan, of which the net outflow of 16.32 million yuan in large orders, net outflow of 19.04 million yuan, net inflow of mid-orders, net inflow of 8.6317 million yuan, and net inflow of small orders.
02. Chip Analysis
Chip Pattern: The current chip pattern of this stock is a dense pattern. In the past 30 days, the chip density has increased from 56% to 76%. During the same period, the stock price rose from 6.58 yuan to 7.58 yuan, an increase of 15.20%.
chip profit and loss: Overall profit chips account for 45.23%, with an average profit of 0.04%, of which 9% of light profit chips account for 9%, 0% of heavy profit chips account for 0%, 1% of heavy trapped chips account for 1%, and 5% of light trapped chips account for 5.
chip cost: main cost is 7.31 yuan, the average cost is 7.61 yuan, and the chip intensive cost is 7.78 yuan, of which 90% of the chips have the highest price of 8.49 yuan, the lowest price is 6.79 yuan, the concentration is 88.87%, the profit ratio of 40.83%, the highest price of 70% chips is 8.04 yuan, the lowest price is 7.08 yuan, the concentration is 93.65%, and the profit ratio is 30.24%.
03. Trading Analysis
Dolphin Stock APP Trading Line Trend Analysis: It is currently in an upward trend, and the short-term trend is stronger than the market. Reduce the volume and callback, pay attention to the adjustment range.
04. Texture Analysis
Company's main business: The company belongs to the pharmaceutical manufacturing industry and is mainly engaged in the research and development, production and sales of pharmaceutical products. The company's products include chemical drugs, biological drugs, nutritional health products, etc., and the treatment areas cover nearly 700 product specifications, including anti-infective drugs, cardiovascular and cerebrovascular drugs, nephropathy and immunomodulatory drugs, tumor treatment drugs, vitamins and nutritional health products.
As of September 30, 2019, North China Pharmaceutical 's operating income was 8.026 billion yuan, and the net profit attributable to the parent company's shareholders was 91.5294 million yuan, an increase of 18.98% year-on-year.
No institutions have conducted research on North China Pharmaceutical in the past three months, and the stock has received relatively low attention from institutions.
Click to download the Dolphin Stock APP, and the smart market-oriented free experience for life
Disclaimer: The information provided on this page is for investors' reference only and does not constitute any investment advice.
